Recently, a multi-center prospective study initiated by Professor Huang Wei from the Union Hospital of Huazhong University of Science and Technology showed that the rate of lymph node metastasis in patients with thyroid cancer in China is high, and the preoperative diagnosis rate is low. Preventive cleaning is an important remedy. Although preventive resection of lymph nodes has not been recommended in the US guidelines, it is still important for Chinese patients to adhere to preventive dissection of cervical lymph nodes.

According to Huang Wei, thyroid cancer is the fastest growing solid malignant tumor. Women and middle-aged people have become the "hardest hit areas" for thyroid cancer. In 2014, the incidence of thyroid cancer in women in China was as high as 18.99/100,000. In order to accumulate data on thyroid cancer in China and promote the development of clinical research on thyroid cancer in China, the top ten medical centers in the United States have completed the “DART Multi-Center Real-World Research on Chinese Thyroid Cancer”, the DTCC study.

In the DTCC study, a total of 2013 patients with thyroid cancer were enrolled. 99% of the patients underwent lymph node dissection at the time of surgery, and 82.3% of the patients had lymph node metastasis after surgery. However, preoperative cervical ultrasonography revealed a suspicious lymph node ratio of only 32.4%. The results of this study confirmed that the lymph node metastasis rate in our patients is quite high, and the preoperative diagnosis rate is low. Preventive cleaning is an important remedy. Huang Wei pointed out that if the preoperative ultrasound compliance rate needs to be improved, if the US guidelines are copied, more patients with thyroid cancer surgery will have recurrence and metastasis.

As for the high rate of lymph node metastasis in patients with thyroid cancer in China, the analysis of jaundice may be related to three reasons: First, patients and doctors in China attach great importance to lymph node metastasis, and the rate of preventive cleaning is high. Second, Chinese doctors routinely use during surgery. Frozen disease examination, the rate of diagnosis is high, the rate of therapeutic clearance is high; the third is that the diagnosis and treatment of patients in China is relatively late, resulting in a high rate of lymph node metastasis.

Huang Wei also pointed out that the diagnosis and treatment of thyroid cancer in China is gradually standardized, but there is still no standardized process and tools for long-term follow-up after operation. The quality of follow-up of primary medical units is not high. The postoperative follow-up of thyroid cancer is that patient compliance is not high. The proportion of patients on time is still less than 50%, and the relevant medical team, patient education, and tool platform construction are all in need of improvement.

Test Kits

Diagnostic reagents can be divided into two categories: in vivo diagnostic reagents and in vitro diagnostic reagents. It is mostly a reagent for detection by the reaction between antigen and antibody.
A: Classification of in vitro diagnostic reagents:
1. In vitro biodiagnostic reagents managed as drugs include:
1. Blood type and tissue type reagents;
2. Microbial antigen, antibody and nucleic acid detection reagents;
3. Tumor marker reagents;
4. Immunohistochemistry and human tissue cell reagents;
5. Human genetic testing reagents;
6. Biochips;
7. Allergy diagnostic reagents.

2. In vitro reagents managed as medical devices include:
1. Clinical basic test reagents;
2. Clinical chemistry reagents;
3. Blood gas and electrolyte determination reagents;
4. Vitamin determination reagents;
5. Cell histochemical stains;
6. Autoimmune diagnostic reagents;
7. Microbiological test reagents.
B: According to medical test items, clinical diagnostic reagents can be roughly divided into clinical chemical test reagents, immunology and
Serological testing reagents, hematological and cytogenetic testing reagents, microbiological testing reagents, body fluid excretion
Detection reagents, genetic diagnosis reagents, etc. Among them, the market share of clinical chemistry
The largest, close to 34%; followed by the immunology market, accounting for about 29%. Novel immunodiagnostic reagents and genetic diagnostic tests
The reagent was developed in the late 1980s, and it is the most common diagnostic reagent for all current diagnostic reagents, regardless of technology or market.
The fastest growing product.

Urine Rapid Test Kit,Rapid Test Kit 6-Panel,Toxoplasma rapid test kits,Fecal Occult Blood Test

Jilin Sinoscience Technology Co. LTD , https://www.jlgkscience.com